Delving into the Latest Updates on Galderma Laboratorium GmbH with Synapse

概览

关联

4

项与 Galderma Laboratorium GmbH 相关的临床试验

Non-interventional Study Investigating Photodynamic Therapy With Artificial Daylight Under Routine Clinical Conditions in Patients With Actinic Keratosis (ArtLight)

The objective of this non-interventional study (NIS) is to gain comprehensive insights into the practicability of ADL-PDT with Metvix® in patients with actinic keratoses under real-world conditions.

开始日期2022-11-01

申办/合作机构

Galderma Laboratorium GmbH

NCT02338544 / CompletedN/A

Application of Epiduo(R) PUMP in Daily Practice in Patients With Inflammatory Acne

The purpose of this observational trial is to assess application and convenience of Epiduo® PUMP under daily clinical practice conditions in patients with moderate to severe inflammatory acne.

开始日期2015-01-01

申办/合作机构

Galderma Laboratorium GmbH

NCT01618773 / CompletedN/A

Epiduo in the Long-term Treatment of Moderate to Severe Acne With or Without Concomitant Medication

This observational study is designed to assess the long-term efficacy and safety of Epiduo (alone or in combination with other drugs) under daily clinical practice conditions in patients with moderate to severe inflammatory acne. In addition, the effect of Epiduo on quality of life and patient adherence will be assessed under marketed conditions.

开始日期2012-06-01

申办/合作机构

Galderma Laboratorium GmbH

100 项与 Galderma Laboratorium GmbH 相关的临床结果

登录后查看更多信息

0 项与 Galderma Laboratorium GmbH 相关的专利（医药）

登录后查看更多信息

10

项与 Galderma Laboratorium GmbH 相关的文献（医药）

2024-05-01·JAAD Case Reports

Gender transition during a clinical trial

作者: El-Qadi, Sami I ; Cohen, Joel L

2024-03-01·Mycoses

Activity of amorolfine or ciclopirox in combination with terbinafine against pathogenic fungi in onychomycosis—Results of an in vitro investigation

Article

作者: Odon, Astrid ; Nabhani, Schafiq ; Jäckel, Andreas ; Riel, Simon ; Schaller, Martin ; Walker, Birgit

AbstractBackgroundOnychomycoses are difficult‐to‐treat fungal infections with high relapse rates. Combining oral and topical antifungal drugs is associated with higher success rates. Additive or synergistic modes of action are expected to enhance treatment success rates.ObjectivesInvestigation of the combined effects of antifungal drugs in vitro with different modes of action and application on clinical isolates from mycotic nails.MethodsIsolates of Trichophyton rubrum, Trichophyton interdigitale and Scopulariopsis brevicaulis were collected from infected toenail specimens of patients with onychomycosis. Susceptibility testing was performed in 96‐well polystyrene plates using a standard stepwise microdilution protocol. Additive or synergistic activity at varying concentrations was investigated by the checkerboard method.ResultsCombining terbinafine with amorolfine tended to be more effective than terbinafine in conjunction with ciclopirox. In most combinations, additive effects were observed. Synergy was detected in combinations with involving amorolfine in S. brevicaulis. These additive and synergistic interactions indicate that combined therapy with topical amorolfine and oral terbinafine is justified. Sublimation of amorolfine (and terbinafine) may enhance the penetration in and through the nail plate, and support treatment efficacy.ConclusionsThese in vitro results support the notion that combining oral terbinafine and topical amorolfine is beneficial to patients with onychomycosis, particularly if the pathogen is a non‐dermatophyte fungus such as S. brevicaulis.

2023-12-01·Archives of dermatological research

Silica-based microencapsulation used in topical dermatologic applications.

Review

作者: Green, Lawrence J ; Erlich, Maya ; Toledano, Ofer ; Bhatia, Neal D ; Spizuoco, Amy ; Goodyear, Benjamin C ; York, Jean Philippe ; Jakus, Jeannette

Microencapsulation has received extensive attention because of its various applications. Since its inception in the 1940s, this technology has been used across several areas, including the chemical, food, and pharmaceutical industries. Over-the-counter skin products often contain ingredients that readily and unevenly degrade upon contact with the skin. Enclosing these substances within a silica shell can enhance their stability and better regulate their delivery onto and into the skin. Silica microencapsulation uses silica as the matrix material into which ingredients can be embedded to form microcapsules. The FDA recognizes amorphous silica as a safe inorganic excipient and recently approved two new topical therapies for the treatment of rosacea and acne. The first approved formulation uses a novel silica-based controlled vehicle delivery technology to improve the stability of two active ingredients that are normally not able to be used in the same formulation due to potential instability and drug degradation. The formulation contains 3.0% benzoyl peroxide (BPO) and 0.1% tretinoin topical cream to treat acne vulgaris in adults and pediatric patients. The second formulation contains silica microencapsulated 5.0% BPO topical cream to treat inflammatory rosacea lesions in adults. Both formulations use the same amorphous silica sol-gel microencapsulation technology to improve formulation stability and skin compatibility parameters.

100 项与 Galderma Laboratorium GmbH 相关的药物交易

登录后查看更多信息

100 项与 Galderma Laboratorium GmbH 相关的转化医学

登录后查看更多信息